* Drug Royalty Corp. Inc., of Toronto, paid $1.5 millionto TPL Phytogen Inc., of British Columbia, in exchangefor a percentage of revenues from paclitaxel.

* Isis Pharmaceuticals Inc., of Carlsbad, Calif., startedPhase II trials of ISIS 2303, an antisense inhibitor ofintercellular adhesion molecule-1. The compound isbeing developed in collaboration with Germany-basedBoehringer Ingelheim GmbH.

* OncorMed Inc., of Gaithersburg, Md., extended for fiveyears its agreement with the Hereditary Cancer Instituteand Creighton University. OncorMed has exclusiveworldwide rights to HCI's hereditary database and addedexclusive worldwide commercialization rights to HCI'sDNA library.

* Paraxel International Corp., a Boston-based contractresearch organization, opened offices in Milan, Italy, andKobe, Japan.

* Therexsys Ltd., of Staffordshire, England, signed anagreement with Gryphon Sciences, of South SanFrancisco, to evaluate Gryphon's chemical ligationtechnologies in Therexsys' targeted gene-delivery system.

* Allelix Biopharmaceuticals Inc., of Toronto, began aPhase I/II trial of ALX40-4C for cytomegalovirus.

* CellPro Inc., of Seattle, and Corange International Ltd.,of Bermuda and London, reached a definitive agreementto terminate their December 1993 collaboration. Corangeis paying $30 million for 1 million CellPro shares. (SeeBioWorld Today, May 2, 1995, p. 1.)

(c) 1997 American Health Consultants. All rights reserved.